IP Library › Granted Patent US 8,506,934
Granted Patent B2
US 8,506,934 · App. 12/649,320 · Granted Aug 13, 2013

Methods for detection of biological substances

Inventor: Robert I. Henkin (Bethesda, MD)
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,506,934
App. No.
12/649,320
Granted
Aug 13, 2013
Kind
B2
Abstract

The invention is directed to a method of detecting a biological substance in the nasal secretion and diagnosing a disease following the detection of the biological substance wherein the biological substance is not related to a respiratory disease. The invention also provides treatment of the diseases following the detection of the biological substance and/or diagnosis of the disease. In some embodiments, the diseases are cancer, hepatitis, smell loss, taste loss, diabetes, and leprosy. The invention also provides a kit for diagnosing a disease. The present invention includes methods of analyzing samples from the nose for the detection of biological substances. In particular, nasal secretion or nasal mucus is collected and analyzed for biological substances. The results of this analysis are then suitable for use in diagnosis, prognosis, and determination of suitability of therapeutic interventions.

Claims (18)

1. A method of diagnosing hyposmia or anosmia in a human, the method comprising: (i) obtaining a nasal mucus specimen from the human; (ii) detecting a cyclic nucleotide level in said nasal mucus specimen; (iii) comparing said cyclic nucleotide level to a cyclic nucleotide level of a control population; and (iv) diagnosing said hyposmia or anosmia in the human based on a decreased level of said cyclic nucleotide for said nasal mucus specimen compared to the cyclic nucleotide level of the control population, wherein the cyclic nucleotide level is detected by an immunoassay, and wherein the method further comprises determining detection (DT) and recognition (RT) thresholds and magnitude estimation (ME) for four odorants: pyridine, nitrobenzene, thiophene and amyl acetate.

2. The method of claim 1 , wherein hyposmia is diagnosed.

3. The method of claim 1 , wherein said cyclic nucleotide is cyclic adenosine monophosphate (cAMP) or cyclic guanosine monophosphate (cGMP).

4. The method of claim 1 , wherein the detecting or the diagnosing is implemented with a computer.

5. The method of claim 1 , wherein said nasal mucus specimen is collected on a sample collection device by passing it into a nostril.

6. The method of claim 1 , wherein said nasal mucus specimen is collected with a collection device comprising a swab, a wooden spatula, a cotton ball, a filter, a gauze pad, an absorbent-tipped applicator, a capillary tube, or a pipette.

7. The method of claim 1 , further comprising treating said hyposmia or anosmia.

8. The method of claim 7 , wherein said treating comprises administering a phosphodiesterase inhibitor.

9. The method of claim 8 , where said phosphodiesterase inhibitor is theophylline.

10. The method of claim 8 , wherein said administering is by oral or nasal administration.

11. The method of claim 8 , wherein said phosphodiesterase inhibitor is formulated as a powder.

12. The method of claim 8 , wherein said phosphodiesterase inhibitor is formulated as a liquid.

13. The method of claim 8 , wherein said administering is performed daily.

14. The method of claim 1 , wherein anosmia is diagnosed.

15. The method of claim 1 , wherein said cyclic nucleotide is cyclic adenosine monophosphate (cAMP).

16. The method of claim 1 , wherein said cyclic nucleotide is cyclic guanosine monophosphate (cGMP).

17. The method of claim 1 , wherein the immunoassay is a luminescent immunoassay or a fluorescence immunoassay.

18. The method of claim 7 , wherein the immunoassay is a luminescent immunoassay or a fluorescence immunoassay.

Assignments (2)
CHANGE OF ADDRESS Recorded Oct 4, 2021
From: CYRANO THERAPEUTICS, INC.
To: CYRANO THERAPEUTICS, INC.
Reel/Frame 057697/0322 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 30, 2017
From: HENKIN, ROBERT I.
To: CYRANO THERAPEUTICS, INC.
Reel/Frame 041798/0269 →
Continuity (4)
Division 11415942 · May 1, 2006
Provisional Application 60743495 · Mar 15, 2006
Provisional Application 60676252 · Apr 29, 2005
Related Publication 20100227875A1 · Sep 9, 2010